
WuXi Biologics (Cayman)
WXIBF | OTC
$5.94
-$0.21 (-3.41%)
At close: Nov 16, 2026, 1:57 PM ET
$6.00
+$0.06 (+1.01%)
Pre-market:
Nov 16, 2026, 8:05 AM ET
WuXi Biologics (Cayman) Company Profile
Company profile explainedCompany Profile
WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international markets. The company also offers expert consultation in biopharmaceutical technology, facilitates international sales contracting, develops and performs advanced testing services, and manages sales and marketing initiatives. Furthermore, it provides clinical and manufacturing support for biologics, manufactures and distributes medical products, serves as a contract development and manufacturing organization (CDMO) for vaccines, and functions as a material supplier. WuXi Biologics maintains significant strategic collaborations with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc. The organization, founded in 2014, is headquartered in Wuxi, China.
Key Executives
| Name | Position |
|---|---|
| Jian Dong | Chief Executive Officer of WuXi Vaccines |
| Zhisheng Chen | Chief Executive Officer & Executive Director |
| Lihua Yu | Chief Operating Officer & Senior Vice President |
| Ming Tu | Chief Financial Officer & Executive Vice President |
| Angus Scott Marshall Turner | Senior Vice President and Head of Global BD & Alliance Management |
| Ge Li | Founder & Chairman |
| He Wang | General Counsel, Chief Compliance Officer, SVP and Head of Legal & Compliance Department |
| Jijie Gu | Chief Scientific Officer & President of Global Biologics Research |
| Lina Fan | Senior Vice President & Head of Investor Relations |
| Xiaohui Liu | Executive VP & Chief Human Resources Officer |
| Xuejun Gu | CTO, Chief Client Officer, EVP of Global Biologics Development Department & Executive Director |
WuXi Biologics (Cayman)

| Country | China |
| IPO Date | Jan 30, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13,252 |
| CEO | Zhisheng Chen |
Contact Details
No. 108, Meiliang Road Wuxi,
JS 214092 China
Stock Details
| Ticker Symbol | WXIBF |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | G97008117 |
| ISIN Number | KYG970081173 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove WXIBF